Someone did me a favor after I wrote about treosulfan

A family office came for me

One of you has done a short string of potentially very large favors for me after I wrote about treosulfan and in follow on discussions after prompting 20 or so people for a capital raise of $1-3.5M USD for a specific situation.

If a relationship is built there, I suspect I’ll be making a lot of dollars in future tax years & the blog will be something a lot smaller than it is now. The reason I think this person did this beyond being in a position to, is they knew someone who used busulfan who would have used treosulfan that died from AML/BMT. Positive business development in prior discussions with other coverage was also mentioned but I suppose I’ll figure out their true motivations later if it all works out. Their clients were clear in their intention that they just want to make money.

I was okay with the content I put together on Treosulfan and soon I’ll have more than a poor PnL to show for it with alive people celebrating a lack of cancer at the end of next year. Medexus on the other hand has turned into this poorly run, overly paid, mismanaged M&A specialty pharma asset company that may self-destruct on leverage before it can even purchase the rights to sell treosulfan (depends entirely on Medac/BMO). To see Medexus blow up is probably something Craig Mull thinks about for M&A at Cipher Pharmaceuticals.

The submission for treosulfan should be within weeks to months, met with a quick turnaround of 2-6 months (SOURCE ANON 2nd hand description: 2024 BLOOM BURTON AND CO conference) and first commercial use happening around the start of 2025 in the US. It’s a big win for leukemia and a bunch of other conditions that utilize alkylating agents for bone marrow conditioning in treatment and IMV most physicians probably will switch simply to avoid any concern of hepatotoxicity of busulfan. There’s also a business— Jazz Pharmaceuticals. They own defibrotide and they stand to lose a low 9 figure business from treosulfan being more widely used (beyond simply its label). Its main use is in addressing complications from busulfan.

With the creation of these types of relationships with people, there’s some responsibility I feel that’s aligned with protecting any information they have. Albeit eventually it seems like someone’s going to pick this up. the business is dead simple (none of this pharma nonsense) and in a discoverable position, so fintwit or VIC or MCC is eventually going to find it and there’s going to be a dialog. When that happens, I’ll be happy to say what I’m allowed to.